MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, VERA had $262,079K increase in cash & cash equivalents over the period. -$241,734K in free cash flow.

Cash Flow Overview

Change in Cash
$262,079K
Free Cash flow
-$241,734K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Proceeds from issuance of common...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchase of marketable securitie...
    • Net loss
    • Payment of issuance costs and un...
    • Others

Cash Flow
2025-12-31
Net loss
-299,615
Depreciation and amortization
468
Accretion of discount and amortization of premium on purchase of debt securities
-6,981
Accretion of loan exit fee and amortization of loan costs, net
1,857
Reduction in the carrying amount of operating lease right-of-use assets
1,449
Stock-based compensation
37,926
Payment of vt-109 license fee
800
Prepaid expense and other current assets
3,928
Other assets
-51
Accounts payable
13,910
Accrued and other liabilities
14,442
Operating lease liabilities
-1,483
Net cash used in operating activities
-241,104
Payment of vt-109 license fee
800
Purchase of property and equipment
630
Purchase of marketable securities
310,446
Proceeds from maturities of marketable securities
506,162
Proceeds from sale of marketable securities
0
Net cash provided by (used in) investing activities
194,286
Proceeds from exercise of stock options and employee stock purchase plan
6,981
Proceeds from refinancing under loan and security agreement, net
23,338
Payment of deferred issuance costs related to unfunded loan commitments
3,517
Proceeds from short swing settlement
500
Proceeds from borrowings, net of costs
0
Repurchase of common stock
0
Proceeds from issuance of common stock in follow-on offerings
300,000
Payment of issuance costs and underwriting fees related to follow-on offerings
18,405
Net cash provided by financing activities
308,897
Net increase in cash and cash equivalents
262,079
Cash and cash equivalents, beginning of year
92,646
Cash and cash equivalents, end of year
354,725
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock in...$300,000K Proceeds fromrefinancing under loan and...$23,338K Proceeds from maturitiesof marketable...$506,162K Proceeds from exercise ofstock options and...$6,981K Proceeds from short swingsettlement$500K Net cash provided byfinancing activities$308,897K Net cash provided by(used in) investing...$194,286K Canceled cashflow$21,922K Canceled cashflow$311,876K Net increase in cashand cash...$262,079K Canceled cashflow$241,104K Payment of issuancecosts and...$18,405K Payment of deferredissuance costs related to...$3,517K Stock-based compensation$37,926K Accrued and otherliabilities$14,442K Accounts payable$13,910K Accretion of loan exit feeand amortization of...$1,857K Reduction in the carryingamount of operating...$1,449K Payment of vt-109license fee$800K Depreciation andamortization$468K Other assets-$51K Purchase of marketablesecurities$310,446K Payment of vt-109license fee$800K Purchase of property andequipment$630K Net cash used inoperating activities-$241,104K Canceled cashflow$70,903K Net loss-$299,615K Accretion of discount andamortization of premium on...-$6,981K Prepaid expense andother current assets$3,928K Operating leaseliabilities-$1,483K

Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc. (VERA)